Recent Updates
Recently added Catalysts
AXGN

AxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014

Key Takeaway: ALACHUA, Fla., July 15, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close o

Full Press Release Details

ALACHUA, Fla., July 15, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the markets.
The Company will host a conference call and webcast for the investment community on Monday, August 4, 2014 at 4:30 PM ET. Investors within the United States interested in participating are invited to call 1.877.674.2413 and reference the Participant Passcode 71503642. All other participants can use the dial-in number 1.914.495.8604, using the same Participant Passcode. To access the webcast online, or to listen to a replay following the event, please visit the Company's website at http://www.AxoGenInc.com and select 'Investor Relations.'
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance Nerve Graft is processed in the United States by AxoGen. AxoGuard Nerve Connector and AxoGuard Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.
To receive email alerts directly from AxoGen, please click here http://www.AxoGenInc.com.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/07/prweb12015600.htm

Related Links

Contact Data

Lee Robert "Bob" Johnston Jr, CFO

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: Jul 15, 2014